Last edition
News about "specialty segments such as critical care and chron"
Wockhardt Q1 Loss Widens to INR 108 Crore on US Subsidiary Liquidation
The loss was mainly driven by a INR 97 crore goodwill impairment following the company’s permanent exit from the US generics market and the voluntary liquidation of its Delaware-based subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC.
Specialty Segments Such As Critical Care And Chron | 11/08/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members